Open AccessLaboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania
Author(s) -
Diana Faini,
Aneth Vedastus Kalinjuma,
Andrew Katende,
Gladys Mbwaji,
Dorcas Mnzava,
Amiyuri,
Tracy R. Glass,
Hansjakob Furrer,
Christoph Hatz,
David R. Boulware,
Emílio Letang
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001899
Subject(s) - medicine , hazard ratio , meningitis , interquartile range , confidence interval , lumbar puncture , fluconazole , cryptococcosis , proportional hazards model , pediatrics , immunology , cerebrospinal fluid , antifungal , dermatology
Cryptococcal antigen (CrAg) screening in persons with advanced HIV/AIDS is recommended to prevent death. Implementing CrAg screening only in outpatients may underestimate the true CrAg prevalence and decrease its potential impact. Our previous 12-month survival/retention in CrAg-positive persons not treated with fluconazole was 0%.